Get the Stockscreener App
1.35
1.09%
-0.02
After Hours:
1.35
Pliant Therapeutics Inc stock is traded at $1.35, with a volume of 2.67M.
It is down -1.09% in the last 24 hours and down -14.78% over the past month.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.
See More
Previous Close:
$1.37
Open:
$1.35
24h Volume:
2.67M
Relative Volume:
1.64
Market Cap:
$82.88M
Revenue:
$5.03M
Net Income/Loss:
$-185.41M
P/E Ratio:
-0.4369
EPS:
-3.09
Net Cash Flow:
$-139.79M
1W Performance:
+5.04%
1M Performance:
-14.78%
6M Performance:
-90.18%
1Y Performance:
-88.87%
1-Day Range:
$1.31
$1.395
1-Week Range:
$1.22
$1.4093
52-Week Range:
$1.1001
$16.10
Pliant Therapeutics Inc Stock (PLRX) Company Profile
Name
Pliant Therapeutics Inc
Sector
Industry
Phone
650-481-6770
Address
331 OYSTER POINT BOULEVARD, SOUTH SAN FRANCISCO, CA
Compare PLRX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PLRX
Pliant Therapeutics Inc
|
1.35 | 82.26M | 5.03M | -185.41M | -139.79M | -3.09 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 25.81B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.85 | 111.46B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 40.37M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.16 | 6.19B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
489.52 | 64.44B | 14.09B | 4.50B | 2.96B | 39.28 |
Pliant Therapeutics Inc Stock (PLRX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-04-25 | Resumed | Cantor Fitzgerald | Neutral |
| Mar-04-25 | Downgrade | Needham | Buy → Hold |
| Mar-03-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-03-25 | Downgrade | Stifel | Buy → Hold |
| Feb-10-25 | Downgrade | Canaccord Genuity | Buy → Hold |
| Feb-10-25 | Downgrade | Citigroup | Buy → Neutral |
| Feb-10-25 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Feb-10-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Feb-10-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-10-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Feb-10-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Sep-09-24 | Resumed | Leerink Partners | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| May-18-23 | Initiated | Canaccord Genuity | Buy |
| Apr-13-23 | Initiated | Robert W. Baird | Outperform |
| Dec-14-22 | Initiated | Stifel | Buy |
| Dec-07-22 | Initiated | JP Morgan | Overweight |
| Sep-01-22 | Initiated | Citigroup | Buy |
| Jul-20-22 | Initiated | SVB Leerink | Outperform |
| May-25-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-10-21 | Initiated | Oppenheimer | Outperform |
| Nov-24-21 | Initiated | RBC Capital Mkts | Outperform |
| Nov-03-21 | Initiated | H.C. Wainwright | Buy |
| Apr-20-21 | Initiated | BTIG Research | Buy |
| Apr-05-21 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Citigroup | Buy |
| Jun-29-20 | Initiated | Cowen | Outperform |
| Jun-29-20 | Initiated | Needham | Buy |
| Jun-29-20 | Initiated | Piper Sandler | Overweight |
View All
Pliant Therapeutics Inc Stock (PLRX) Latest News
Pliant Therapeutics presents new fibrosis treatment data By Investing.com - Investing.com Canada
Pliant Therapeutics Presents Clinical and Preclinical Data at th - GuruFocus
Pliant Therapeutics presents new fibrosis treatment data - Investing.com
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference | PLRX Stock News - GuruFocus
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society ... - Eagle-Tribune
Pliant Therapeutics Presents Clinical and Preclinical Data at the American Thoracic Society International Conference - GlobeNewswire
Breakthrough: Pliant's New Lung Disease Drug Outperforms Standard Treatment in Latest Clinical Data - Stock Titan
How Are Things Looking For Pliant Therapeutics Inc (NASDAQ: PLRX) For The Short Term? - Stocksregister
Cautious Hold Rating on Pliant Therapeutics Amid Clinical and Financial Uncertainties - TipRanks
Another Bay Area biotech company announces layoffs - MSN
Pliant Therapeutics Reports Q1 2025 Financial Results - TipRanks
Pliant (PLRX) Prepares to Release Topline Results from BEACON-IP - GuruFocus
Pliant (PLRX) Prepares to Release Topline Results from BEACON-IPF Trial | PLRX Stock News - GuruFocus
Pliant Therapeutics reports Q1 EPS (92c), consensus (62c) - TipRanks
Pliant Therapeutics (PLRX) Advances in Clinical Trials and Oncology Research | PLRX Stock News - GuruFocus
Pliant Therapeutics Provides Corporate Update and Reports First Quarter 2025 Financial Results - GlobeNewswire
Market Watch Highlights: Pliant Therapeutics Inc (PLRX) Ends on an Downturn Note at 1.43 - DWinneX
Pliant Therapeutics Cuts Workforce by Nearly Half - Powder & Bulk Solids
Bay Area biotech company Pliant Therapeutics slashes staff after losing $655 million in value - MSN
Pliant cuts workforce by 45% following lung trial termination - Clinical Trials Arena
Pliant Therapeutics to cut 45% of workforce (PLRX:NASDAQ) - Seeking Alpha
Pliant Therapeutics (PLRX) Restructures to Prolong Financial Res - GuruFocus
Pliant Therapeutics Reduces Workforce as Part of Strategic Realignment - MarketWatch
Pliant Therapeutics (PLRX) Restructures to Prolong Financial Resources | PLRX Stock News - GuruFocus
Pliant Therapeutics announces workforce reduction By Investing.com - Investing.com India
Pliant Therapeutics announces workforce reduction - Investing.com
Pliant Therapeutics Announces Major Workforce Reduction - TipRanks
Pliant Therapeutics Announces Workforce Reduction and Cost Saving Initiatives to Support Late-Stage Clinical Trials - Nasdaq
Pliant Therapeutics Announces Strategic Realignment of Workforce and Operations - GlobeNewswire
Pliant Therapeutics Slashes Nearly Half its Workforce While Awaiting Crucial IPF Drug Results - Stock Titan
You might want to take a look at Pliant Therapeutics Inc (PLRX) now - Sete News
Pliant Therapeutics Inc [PLRX] stock was sold by Coulie Bernard at the price of US$0.59 million - knoxdaily.com
Market Momentum: Pliant Therapeutics Inc (PLRX) Registers a 0.68 Increase, Closing at 1.48 - DWinneX
Stock Performance Spotlight: Cg Oncology Inc (CGON) Ends the Day at 26.94, Down by -3.68 - DWinneX
Pliant Therapeutics Inc (PLRX)’s highs and lows: A closer look at its stock price fluctuations - uspostnews.com
Legal & General Group Plc Grows Stock Holdings in Pliant Therapeutics, Inc. (NASDAQ:PLRX) - Defense World
Pliant Therapeutics Inc: A Year of Highs, Lows, and Market Resilience - investchronicle.com
Press Release Distribution & PR Platform - ACCESS Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant Therapeutics, Inc.PLRX - Louisiana First News
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Pliant ... - Bluefield Daily Telegraph
Pliant Therapeutics discovers new integrin αvβ1, αvβ6 and/or αvβ8 antagonists - BioWorld MedTech
Pliant Therapeutics Inc’s Market Journey: Closing Weak at 3.03, Down -1.62 - DWinneX
PLRXPliant Therapeutics, Inc. Latest Stock News & Market Updates - Stock Titan
Healthy Upside Potential: Pliant Therapeutics Inc (PLRX) - Sete News
Market Recap Check: Pliant Therapeutics Inc (PLRX)’s Positive Finish at 1.54, Up/Down 2.67 - DWinneX
Pliant Therapeutics Inc (PLRX)’s stock price in review: A technical analysis - uspostnews.com
Pliant Therapeutics, Inc. (NASDAQ:PLRX) Shares Bought by JPMorgan Chase & Co. - Defense World
Pliant Therapeutics Inc Stock (PLRX) Financials Data
Revenue
Net Income
Cash Flow
EPS
Pliant Therapeutics Inc Stock (PLRX) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Cummings Keith Lamont | Chief Financial Officer |
Jan 17 '25 |
Sale |
11.20 |
20,148 |
225,680 |
262,608 |
| Hull Hans | Chief Business Officer |
Jan 17 '25 |
Sale |
11.20 |
15,936 |
178,501 |
211,558 |
| Lefebvre Eric | Chief Medical Officer |
Jan 17 '25 |
Sale |
11.20 |
18,478 |
206,974 |
194,574 |
| Cheung Lily | Chief Human Resource Officer |
Jan 17 '25 |
Sale |
11.20 |
3,740 |
41,892 |
24,550 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 17 '25 |
Sale |
11.20 |
13,270 |
148,639 |
80,774 |
| Ouimette Mike | General Counsel & Corp. Sec'y |
Jan 22 '25 |
Sale |
10.99 |
10,230 |
112,462 |
70,544 |
1.89%
3.67%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):